| The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy B Muz, P de la Puente, F Azab, A Kareem Azab Hypoxia, 83-92, 2015 | 1889 | 2015 |
| Spotlight on ixazomib: potential in the treatment of multiple myeloma B Muz, RN Ghazarian, M Ou, MJ Luderer, HD Kusdono, AK Azab Drug design, development and therapy, 217-226, 2016 | 143 | 2016 |
| Hypoxia. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis B Muz, MN Khan, S Kiriakidis, EM Paleolog Arthritis research & therapy 11, 1-9, 2009 | 143 | 2009 |
| 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma P de la Puente, B Muz, RC Gilson, F Azab, M Luderer, J King, S Achilefu, ... Biomaterials 73, 70-84, 2015 | 141 | 2015 |
| Cell trafficking of endothelial progenitor cells in tumor progression P De La Puente, B Muz, F Azab, AK Azab Clinical Cancer Research 19 (13), 3360-3368, 2013 | 121 | 2013 |
| Hypoxia promotes stem cell-like phenotype in multiple myeloma cells B Muz, P De La Puente, F Azab, M Luderer, AK Azab Blood cancer journal 4 (12), e262-e262, 2014 | 92 | 2014 |
| Molecularly targeted therapies in multiple myeloma P de la Puente, B Muz, F Azab, M Luderer, AK Azab Leukemia research and treatment 2014, 2014 | 77 | 2014 |
| Targeting CD47 as a novel immunotherapy for multiple myeloma J Sun, B Muz, K Alhallak, M Markovic, S Gurley, Z Wang, N Guenthner, ... Cancers 12 (2), 305, 2020 | 68 | 2020 |
| The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies B Muz, P De La Puente, F Azab, M Luderer, AK Azab Molecular Cancer Research 12 (10), 1347-1354, 2014 | 63 | 2014 |
| Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA H Larsen, B Muz, TL Khong, M Feldmann, EM Paleolog Arthritis research & therapy 14, 1-18, 2012 | 58 | 2012 |
| Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma P de la Puente, MJ Luderer, C Federico, A Jin, RC Gilson, C Egbulefu, ... Journal of Controlled Release 270, 158-176, 2018 | 56 | 2018 |
| Prolyl hydroxylase domain enzyme 2 is the major player in regulating hypoxic responses in rheumatoid arthritis B Muz, H Larsen, L Madden, S Kiriakidis, EM Paleolog Arthritis & Rheumatism 64 (9), 2856-2867, 2012 | 52 | 2012 |
| Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma C Federico, K Alhallak, J Sun, K Duncan, F Azab, GP Sudlow, ... Nature communications 11 (1), 6037, 2020 | 51 | 2020 |
| PI 3 KCA plays a major role in multiple myeloma and its inhibition with BYL 719 decreases proliferation, synergizes with other therapies and overcomes stroma‐induced resistance F Azab, S Vali, J Abraham, N Potter, B Muz, P de la Puente, M Fiala, ... British journal of haematology 165 (1), 89-101, 2014 | 51 | 2014 |
| The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015; 3: 83–92 B Muz, P de La Puente, F Azab, AK Azab Epub 2016/10/25. doi: 10.2147/HP, 0 | 51 | |
| Localized delivery of cisplatin to cervical cancer improves its therapeutic efficacy and minimizes its side effect profile C Federico, J Sun, B Muz, K Alhallak, PF Cosper, N Muhammad, A Jeske, ... International Journal of Radiation Oncology* Biology* Physics 109 (5), 1483-1494, 2021 | 48 | 2021 |
| Injectable hydrogels for localized chemotherapy and radiotherapy in brain tumors P de la Puente, N Fettig, MJ Luderer, A Jin, S Shah, B Muz, V Kapoor, ... Journal of pharmaceutical sciences 107 (3), 922-933, 2018 | 48 | 2018 |
| Tumor-associated macrophages in multiple myeloma: Advances in biology and therapy J Sun, C Park, N Guenthner, S Gurley, L Zhang, B Lubben, O Adebayo, ... Journal for immunotherapy of cancer 10 (4), 2022 | 47 | 2022 |
| Targeting E-selectin to tackle cancer using uproleselan B Muz, A Abdelghafer, M Markovic, J Yavner, A Melam, NN Salama, ... Cancers 13 (2), 335, 2021 | 43 | 2021 |
| Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy K Alhallak, J Sun, K Wasden, N Guenthner, J O’Neal, B Muz, J King, ... Leukemia 35 (8), 2346-2357, 2021 | 41 | 2021 |
Abdel Kareem AzabAssociate Professor, Biomedical Engineering, University of Texas Southwestern Medical CenterVerified email at utsouthwestern.edu
